<SUBMISSION>
<SECRELEASE-DATETIME> 20201020-163834 ⇐ Metadata from SEC Info (ET)
<SECWEBSITE-DATETIME> 20201020-163832 ⇐ Metadata from SEC Info (ET)
<ACCEPTANCE-DATETIME> 20201020-163759 ⇐ Filing accepted by SEC (ET)
<ACCESSION-NUMBER> 0001193125-20-272903
<TYPE> S-8
<PUBLIC-DOCUMENT-COUNT> 5
<FILING-DATE> 20201020
<DATE-OF-FILING-DATE-CHANGE> 20201020
<EFFECTIVENESS-DATE> 20201020
|
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME> Aligos Therapeutics, Inc.
<CIK> 0001799448
<ASSIGNED-SIC> 2836
<IRS-NUMBER> 000000000
<STATE-OF-INCORPORATION> DE
<FISCAL-YEAR-END> 1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE> S-8
<ACT> 33
<FILE-NUMBER> 333-249568
<FILM-NUMBER> 201248663
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1> ONE CORPORATE DR., 2ND FLOOR
<CITY> SOUTH SAN FRANCISCO
<STATE> CA
<ZIP> 94080
<PHONE> (800) 466-6059
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1> ONE CORPORATE DR., 2ND FLOOR
<CITY> SOUTH SAN FRANCISCO
<STATE> CA
<ZIP> 94080
</MAIL-ADDRESS>
</FILER>
|
<DOCUMENT>
<TYPE> S-8
<SEQUENCE> 1
<FILENAME> d49522ds8.htm
<DESCRIPTION> S-8
<TEXT>
<HTML>
Show <HTML>: 1,018 lines (widest: 254 characters) - 84K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> EX-5.1
<SEQUENCE> 2
<FILENAME> d49522dex51.htm
<DESCRIPTION> EX-5.1
<TEXT>
<HTML>
Show <HTML>: 106 lines (widest: 249 characters) - 12K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> EX-23.2
<SEQUENCE> 3
<FILENAME> d49522dex232.htm
<DESCRIPTION> EX-23.2
<TEXT>
<HTML>
Show <HTML>: 18 lines (widest: 248 characters) - 2K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> GRAPHIC
<SEQUENCE> 4 ⇐ Not a Document/Exhibit
<FILENAME> g49522ex5-1dsp1.jpg
<DESCRIPTION> GRAPHIC
<TEXT>
Show <TEXT>: 98 lines (Unix-to-Unix encoding) - 6K bytes
</TEXT>
</DOCUMENT>
|
<DOCUMENT>
<TYPE> GRAPHIC
<SEQUENCE> 5 ⇐ Not a Document/Exhibit
<FILENAME> g49522ex5-1dsp2.jpg
<DESCRIPTION> GRAPHIC
<TEXT>
Show <TEXT>: 74 lines (Unix-to-Unix encoding) - 5K bytes
</TEXT>
</DOCUMENT>
|
</SUBMISSION> |
↑Top |